Disease · MONDO_0044881
hematopoietic and lymphoid cell neoplasm
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. hematopoietic and lymphoid cell neoplasm. Diseases, record MONDO_0044881. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0044881
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
HEMOLYMPHORETICULAR tumor, malignant, haematological neoplasm, haematological tumour, haematopoietic and lymphoid neoplasms, haematopoietic cancer, haematopoietic cell tumour, haematopoietic malignancy, NOS, haematopoietic neoplasm, haematopoietic neoplasms including lymphomas, haematopoietic tumour, hematologic cancer, hematologic malignancy, hematologic neoplasm, hematological neoplasm, hematological tumor, hematopoietic and lymphoid neoplasms, hematopoietic cancer, hematopoietic cell tumor, hematopoietic malignancy, NOS, hematopoietic neoplasm, hematopoietic neoplasms including lymphomas, hematopoietic tumor, hematopoietic, Including myeloma, malignant haematopoietic neoplasm, malignant hematologic neoplasm, malignant hematopoietic neoplasm
- Open Targets
- Highest stage of its drugs
- Approval, for 2 of its 251 drugs, from EMA Human Drugs and PMDA
- Open Targets
Drugs251
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| POSACONAZOLE | CHEMBL1397 | Small molecule | Approval | PMDA | 2 | 1 | 1 | Drugs and targets |
| DOROCUBICEL | CHEMBL5314825 | Cell | Approval | EMA Human Drugs | 1 | 0 | 0 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 3 | ClinicalTrials.gov | 133 | 133 | 133 | Drugs and targets |
| FLUDARABINE | CHEMBL1568 | Small molecule | Phase 3 | ClinicalTrials.gov | 74 | 74 | 74 | Drugs and targets |
| MYCOPHENOLATE MOFETIL | CHEMBL1456 | Small molecule | Phase 3 | ClinicalTrials.gov | 73 | 73 | 73 | Drugs and targets |
| FLUDARABINE PHOSPHATE | CHEMBL1096882 | Small molecule | Phase 3 | ClinicalTrials.gov | 58 | 58 | 58 | Drugs and targets |
| TACROLIMUS ANHYDROUS | CHEMBL269732 | Small molecule | Phase 3 | ClinicalTrials.gov | 46 | 46 | 46 | Drugs and targets |
| ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | CHEMBL2108981 | Phase 3 | ClinicalTrials.gov | 43 | 43 | 0 | Drugs and targets | |
| FILGRASTIM | CHEMBL1201567 | Protein | Phase 3 | ClinicalTrials.gov | 42 | 42 | 28 | Drugs and targets |
| CYCLOSPORINE | CHEMBL160 | Protein | Phase 3 | ClinicalTrials.gov | 34 | 34 | 34 | Drugs and targets |
1 to 10 of 251
See all 251 drugsTargets265
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| KIT | Mast/stem cell growth factor receptor Kit | 9 | Stem cell growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| TUBB | Tubulin | 9 | Tubulin beta inhibitor; Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/203068 | Drugs and targets |
| TUBB1 | Tubulin | 9 | Tubulin beta inhibitor; Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/81027 | Drugs and targets |
| TUBB2A | Tubulin | 9 | Tubulin beta inhibitor; Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/7280 | Drugs and targets |
| TUBB2B | Tubulin | 9 | Tubulin beta inhibitor; Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/347733 | Drugs and targets |
| TUBB3 | Tubulin | 9 | Tubulin beta inhibitor; Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/10381 | Drugs and targets |
| TUBB4A | Tubulin | 9 | Tubulin beta inhibitor; Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/10382 | Drugs and targets |
| TUBB4B | Tubulin | 9 | Tubulin beta inhibitor; Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/10383 | Drugs and targets |
| TUBB6 | Tubulin | 9 | Tubulin beta inhibitor; Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/84617 | Drugs and targets |
| TUBB8 | Tubulin | 9 | Tubulin beta inhibitor; Tubulin inhibitor | Phase 2 | https://conductscience.org/library/genes/347688 | Drugs and targets |
1 to 10 of 265
See all 265 targetsTrials377
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 14 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02407990 | Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors | Phase 1 | 451 | 2021-11-17 | Advanced Cancer | TISLELIZUMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01119066 | HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies | Phase 2 | 422 | 2022-08-05 | Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Multiple Myeloma | BUSULFAN, CLOFARABINE, CYCLOPHOSPHAMIDE, FLUDARABINE, MELPHALAN, THIOTEPA | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00003816 | Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer | Phase 2/3 | 361 | 2021-08-13 | Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Nonmalignant Neoplasm, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific | BUSULFAN, CARBOPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE, FLUDARABINE PHOSPHATE, MELPHALAN, THIOTEPA | Its record names the disease | ClinicalTrials.gov |
| NCT02345850 | Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301) | Phase 3 | 346 | 2021-12-21 | Acute Leukemia, Myelodysplasia | CYCLOPHOSPHAMIDE, METHOTREXATE, TACROLIMUS ANHYDROUS | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00303719 | Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy | Phase 2 | 342 | 2020-05-12 | Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm, Myelodysplastic Syndromes | CYCLOPHOSPHAMIDE, CYCLOSPORINE, FLUDARABINE, MYCOPHENOLATE MOFETIL | Its record names the disease | ClinicalTrials.gov |
| NCT00176930 | Stem Cell Transplant for Hematological Malignancy | Not applicable | 330 | 2021-01-22 | Leukemia, Myeloid, Chronic, AML, Leukemia, Lymphocytic, Acute, MDS, Leukemia, Lymphocytic, Chronic, JMML, Hodgkin's Disease, Non-hodgkin's Lymphoma, Multiple Myeloma | BUSULFAN, CYCLOPHOSPHAMIDE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00544115 | Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders | Phase 2 | 260 | 2023-05-10 | Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Precancerous/Nonmalignant Condition | BUSULFAN, CYCLOPHOSPHAMIDE, CYCLOSPORINE, ETOPOSIDE, FLUDARABINE PHOSPHATE, MELPHALAN, METHOTREXATE, MYCOPHENOLATE MOFETIL, SIROLIMUS, TACROLIMUS ANHYDROUS | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00412360 | Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501) | Phase 3 | 224 | 2015-12-21 | Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Natural Killer Cell Lymphoblastic Leukemia/Lymphoma | CYCLOPHOSPHAMIDE, CYCLOSPORINE, FLUDARABINE, MYCOPHENOLATE MOFETIL | Its record names the disease | ClinicalTrials.gov |
| NCT00309842 | Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases | Phase 2 | 213 | 2020-09-10 | Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis, MDS, Refractory Anemia, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Non-Hodgkin's Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes | CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00134004 | Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer | Phase 2 | 210 | 2015-08-24 | Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes | CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE, MYCOPHENOLATE MOFETIL, TACROLIMUS ANHYDROUS | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 377
See all 377 trialsComparisons in its trials93
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| BGB-A317 Phase 1A vs BGB-A317 Phase 1B: deaths from any cause | 97 of 116 | 249 of 335 | 451 | NCT02407990 | Trial comparisons |
| BGB-A317 Phase 1A vs BGB-A317 Phase 1B: serious adverse events | 40 of 116 | 131 of 335 | 451 | NCT02407990 | Trial comparisons |
| High Risk Patients vs Standard Risk Patients: Acute Graft-Versus-Host Disease | 2 of 13 | 79 of 292 | 305 | NCT00303719 | Trial comparisons |
| High Risk Patients vs Standard Risk Patients: Serious Adverse Events | 0 of 13 | 47 of 292 | 305 | NCT00303719 | Trial comparisons |
| High Risk Patients vs Standard Risk Patients: Overall Survival | 8 of 13 | 181 of 292 | 305 | NCT00303719 | Trial comparisons |
| High Risk Patients vs Standard Risk Patients: Transplant Related Mortality | 2 of 13 | 40 of 292 | 305 | NCT00303719 | Trial comparisons |
| High Risk Patients vs Standard Risk Patients: deaths from any cause | 6 of 13 | 124 of 292 | 305 | NCT00303719 | Trial comparisons |
| High Risk Patients vs Standard Risk Patients: Neutrophil and Donor Cell Engraftment | 12 of 13 | 289 of 292 | 305 | NCT00303719 | Trial comparisons |
| High Risk Patients vs Standard Risk Patients: serious adverse events | 1 of 13 | 53 of 292 | 305 | NCT00303719 | Trial comparisons |
| Single UCB Transplant vs Double UCB Transplant: Number of Participants With Engraftment Syndrome | 11 of 112 | 7 of 108 | 220 | NCT00412360 | Trial comparisons |
1 to 10 of 93
See all 93 comparisons in its trialsPapers from its trials120
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0044881
GET https://conductscience.org/api/diseases/v1/MONDO_0044881/drugs?page=2